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Introduction
Spinal Muscular Atrophy (SMA) is one of many neuromuscular diseases affect
ing motor neurons and skeletal muscles. This disorder causes deterioration of
the motor neurons (specifically the Anterior Horn Cells of the spinal cord).
These motor neurons that control muscles are selectively destroyed resulting
in varying degrees of atrophy, weakness and paralysis of the trunk and limb
muscles. In this first half of the thesis report, various aspects of Spinal
Muscular Atrophy, including history, anatomy/ physiology, diagnosis, theories
of its function, types, characteristics, heredity, research, and treatment will
be examined. A second portion of this report focuses upon both illustration and
interactive computer media and animation as a visual introduction to SMA for
the lay audience, patients, and their families.
Spinal Muscular Atrophy has plagued man for generations. Many of the
spinal muscular atrophies bear the names of the pioneering physicians who
were among the first to describe the clinical signs of the disease in medical
literature. Since the turn of the century, several authors have described
patients with progressive muscular dystrophy who demonstrated fascicula-
tions on clinical examination. Initially, this was interpreted as muscular dys
trophy with secondary anterior horn cell changes and, later, as a transition
between, or a combination of muscular dystrophy and progressive spinal mus
cular atrophy.
In 1850, the first form of the disorder, distinct from the muscular dys
trophies, was identified in adult patients by two French physicians, Francois-
Amilcar Aran and Guillaume Benjamin Amand Duchenne. Toward the end of the
19th century, two German doctors, Guido Werdnig and Johann Hoffmann,
described the disease in children. As recently as the early 1950's a team of
Swedish doctors, Eric Klas Henrik Kugelberg and Lisa Welander, identified still
another form of the disease that attacks children.
Anatomy
To understand how SMA affects the motor neurons, it helps to understand
anatomy of the central nervous system. The spinal cord acts as a pathway for
nerve impulses from the brain to travel to various destinations in the body
whether it be to voluntary or involuntary muscle or organs. Within it is the
grey matter which form the
"H"
shaped region surrounded by white matter.
The grey matter of the central nervous system contains large numbers of cell
bodies of neurons. This grey matter includes the cerebral cortex, basal gan
glia, and nuclei of the brain and the grey columns of the spinal cord, (or
"H"
shaped region). (1) The cell bodies of the motor neurons are located in the
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anterior horns of the grey
"H"
shaped region of the spinal cord, hence the
name, anterior horn cells. The axon of the anterior horn cell is an efferent
fiber innervating a skeletal muscle at various points. (2)
It is these anterior horn cells of the spinal cord that SMA attacks caus
ing them to deteriorate. (With the loss of motor neuron function, the muscles
weaken and degenerate). These motor neurons that control muscles are selec
tively destroyed resulting in varying degrees of atrophy, weakness, and paraly
sis of the trunk and limb muscles.
Cause and Theories
All of the spinal muscular atrophies are caused by an abnormal gene or
genes. Genes act as blueprints for the construction of proteins, the basic
building blocks of cells. Exactly how a genetic abnormality leads to the devel
opment of any form of Spinal Muscular Atrophy is not known. Why the motor
neurons are selectively destroyed and why there are so many variations of SMA
are just two of the many questions researchers are trying to answer. Several
theories exist as to how nerve impulses and muscles are affected. The first
theory is a failed impulse. For example, to contract a muscle, a fast impulse
must be sent quickly, smoothly, and follow a series of necessary steps. The
brain sends messages down the spinal cord to the anterior horn cells to be sent
to the awaiting muscle. Somewhere along the anterior horn cell's axon, the
impulse is lost and never reaches the awaiting muscle. Researchers do not
know if the problem lies along the axon within the cell body. (The site of mus
cle innervation is not a problem of SMA but of a similar neuromuscular disease
called Myasthenia Gravis).
A second theory of affected impulses is a partial impulse or stimulation.
After the electrical impulse reaches the anterior horn cell, the impulse is par-
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tially delivered to the muscle. Somewhere part of the message is destroyed
along the axon. The muscle is stimulated to contract slightly, not using its
full potential, or it partially contracts. Often other symptoms are muscle
spasms, or fasciculations, due to constant electrical impulses sent to the
muscle to contract and tremors caused by weakened muscles unable to hold a
steady position. "Watching a patient with diffuse fasciculations is reminiscent
of watching the surface of a pond in summer when the fish are rising: the rip
ples arise here and there with no seeming pattern. ..A fasciculation is an invol
untary discharge of one motor unit resulting in the contraction of all the mus
cle fibers supplied by a single nerve cell. When denervation occurs, the sever
al hundred muscle fibers supplied by a particular nerve may become devoid of
their nerve supply. Ordinarily they atrophy, but reinnervation from a neighbor
ing nerve cell may occur. This results in the accumulation of additional mus
cle fibers within the newly formed motor unit. By a constant process of den
ervation and reinnervation, motor units may come to contain several thousand
muscle fibers rather than a few hundred. ...The origin of the fasciculation is not
clear. It is a spontaneous discharge in some part of the motor nerve. "(3)
Since there are many innervation points of a branch nerve to a muscle,
the defected portion of the nerve could be anywhere along the axon. Therefore,
some muscle fibers of a muscle may be stimulated while other muscle fibers
of the same muscle may be atrophied or weakened due to the lack of/or partial
nerve stimulation as will be discussed later under tissue studies.
Affected Muscles
Spinal muscular atrophy primarily affects the motor neurons that control
muscles of the body. This typically includes the proximal muscles (cord to
elbow, cord to knee) rather than the distal muscles (joint to farthest point) of
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the body. Facial muscles are usually not affected. Affected muscles are the
flexors and extensors of the proximal portions of arms and legs. These
include, the biceps brachaii and triceps, intercostal, muscles in the gluteal
region and pelvic girdle, adductors of the legs, hamstrings, quadriceps, and
hypertrophy in gastrocnemius (calve) muscle.
Types and Characteristics
The spinal muscular atrophies are a group of inherited neuromuscular
diseases that cause varying degrees of weakness and wasting of the trunk and
limb muscles. There are four basic types of SMA, which are classified accord
ing to the severity of weakness, age at onset of symptoms, and distribution of
muscles affected. (4)
Type I, or Infantile Progressive Spinal Muscular Atrophy (Acute Werdnig-
Hoffmann disease), has the earliest onset of symptoms from birth to three
months. These individuals have generalized muscle weakness, weak cry, trou
ble swallowing and sucking, breathing distress usually leading to paralysis of
the legs and arms within three months. "Babies with the infantile type cannot
roll over, raise their heads, or sit without support. ...Because of breathing dis
tress and respiratory infection, life-span rarely exceeds age
two."
(5)
In type II, or Intermediate Spinal Muscular Atrophy, (chronic Werdnig-
Hoffmann disease) the age of onset is six months to three years. Disease char
acteristics include progressive weakness in arms, legs, upper and lower torso,
often with skeletal deformities. "During early childhood, the scoliosis is best
controlled by means of a back brace which provides passive support. Bear in
mind, however, that the child who is walking with great difficulty may be
quite unable to do so when wearing a body jacket. As the children attain their
teenage years, surgery is usually
indicated." (6) The disease progresses rapid-
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ly with this form. While most patients survive to early childhood, respiratory
problems can further shorten life.
The age of onset for type III or Juvenile Spinal Muscular Atrophy
(Kugelberg-Welander disease) is one to fifteen years. Disease characteristics
include weakness in leg and hip muscles which makes it difficult to climb
stairs, stand up, and turns the child's walk into a waddle. In addition, shoul
der, arm, and respiratory muscles are also weakened. Calf muscles are often
enlarged. Youngsters with this type can walk, although with difficulty, at
least ten years after symptoms become apparent. The disease progresses
slowly even though a wheelchair is often required by age 30. Life span is
unaffected.
The fourth and last type, Adult Spinal Muscular Atrophy, (Aran-Duchenne
disease), starts at 18-50 years of age. Characteristics include weakness in
the tongue, hands, or feet, which slowly spreads to other parts of the body. A
relatively mild form of SMA, it has little impact on life expectancy.
Diagnosis
Although not all children and adults with these symptoms have SMA, it is
important to have a thorough neurological examination to establish a diagnosis.
This is to confirm that the symptoms indicate spinal muscular atrophy and not
another condition with similar symptoms.
Diagnosis is made by carefully evaluating the patient's medical history
and by performing a thorough physical examination. The clinical diagnosis is
then confirmed by a series of laboratory tests. Since SMA is a genetic disor
der, an inherited disease that can be passed down from one generation to the
next, it is also important to check family history.
Diagnosis is unclear sometimes when it is difficult to distinguish
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between SMA and other neuromuscular disorders. In these cases, physicians
use tests to help them arrive at a diagnosis. First, the physical evaluation
includes a manual muscle strength test on a scale from 0-5, (five being nor
mal), according to the Medical Research Council Scale. (7) In this test,
strength and range of motion, flexion, extension, internal and external rota
tion, abduction, and adduction are all measured. Distal hand strength measures
include grip strength and flexion in fingers. In addition, the patient's function
and mobility is considered when doing self-care activities to determine inde
pendence or dependence. (8)
"Examination of the deep tendon reflexes is an important part of the
muscle examination. The muscles which are evaluated are those of any stan
dard neurological examination and include the biceps, triceps, supinator, knee,
and ankle jerks together with the superficial reflexes of the abdomen and the
plantar responses. Reflexes for SMA could be described as either absent,
diminished, normal, or hyperactive. In judging whether a reflex is hyperactive,
attention is paid to the spread of the reflex to neighboring muscle groups and,
most importantly, to the degree of "snap" in the muscle contraction.
Ordinarily, when a tendon is tapped, the initial contraction of the muscle has
a rather smooth quality before relaxing. In a hyperactive reflex, the tendon
jerk becomes more jerky than
usual."
(9)
After the initial physical evaluation, more clinical tests may be taken. A
second procedure, or the muscle biopsy, enables a pathologist to determine
whether a disorder is one of the spinal muscular atrophies by studying a small
piece of muscle tissue taken from an individual. The tissue sample taken from
an affected muscle shows distinct differences between healthy muscle and
muscle affected by SMA. Healthy tissue shows muscle fibers to be full and
uniform in size. However, muscle affected by SMA have intermixed healthy, or
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normal, atrophied, and hypertrophied fibers along with large amounts of con
nective and sometimes adipose tissue. "Atrophic fibers are randomly scat
tered and not grouped together. Some atrophic fibers are excessively dark in
oxidative enzyme reactions, perhaps because mitochondria are comparatively
spared and occupy a greater volume of shrinking sarcoplasm... .Based upon a
muscle biopsy, the pathologist cannot tell the clinician whether the lesion
resides in the motor neuron or in the peripheral nerve." (10)
Another diagnostic test is the electromyogram (EMG). By placing small
electrodes in muscle, this test creates a graph that indicates the health of the
body's muscles and nerves, and measures muscle activity. For example, "con
trary to healthy subjects during quiet standing, SMA patients reveal in addition
to the activity of the triceps surae and paraspinal muscles, also the definite
presence of activity in quadriceps, hamstrings as well as the tibial anterior
muscles.. .In other words, muscle of SMA patients in respect to electrical
activity are much more active when compared with the healthy control
group."
(11)
The EMG test has also enabled physicians to understand the activity or
inactivity of certain muscle groups, as they compensate for inactive ones in
the SMA patient. This can be illustrated by one EMG study of healthy verses
SMA patients performing various simple exercises. "In the control group of
healthy subjects bending forward activates all the lumbar muscles and the
muscles of the so-called posterior compartment of the lower limbs (ham
strings, triceps surae) and relax the activity of the quadriceps and abdominal
muscles. None of the quadriceps muscle is activated during this maneuver.
Furthermore, abdominal muscles have been less active when compared with the
activity of other recorded muscle groups. ...The SMA patient in order to perform
this maneuver of bending forward must activate the agonistic and antagonistic
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muscle groups
simultaneously."
(12)
A third clinical test for diagnosing SMA is in administering blood tests
to evaluate the levels of certain enzymes, helping to distinguish the spinal
muscular atrophies from other neuromuscular diseases.
Tissue Studies
It is not clear whether the destruction of motor neurons in spinal muscu
lar atrophy is initiated at the cell body or along the axon. Examination of the
nerves of patients having infantile and juvenile forms reveals a marked deple
tion of large axons and a high percentage of small axons. This aspect of the
pathology, which is still under investigation, could reveal an important clue to
the question of where the genetic defect(s) underlying these diseases are first
manifested.
"Microscopic examination of muscle from patients often reveals small,
underdeveloped fibers which resemble the muscle in a developing fetus. Other
studies have indicated that the diseased muscle resembles that of laboratory
animals in which motor neurons were severed during development. Whether the
appearance of the muscle is an indication that its maturation is somehow
arrested at some crucial point during development, or is the result of deterio
ration of what were once normal muscle fibers is not well understood.
The body is constantly synthesizing new proteins to replace and renew
muscle. One report has indicated that the individuals with spinal muscular
atrophy may have lower than normal rates of muscle protein synthesis. This
suggests that the muscular degeneration they experience may not be due to
ongoing destruction but rather to a lack of the normal renewal necessary to
maintain healthy muscles. Whether this reduced rate of protein synthesis is
caused directly by a genetic abnormality or is merely a secondary result of the
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disease process is not yet known.
Another observation that remains unexplained is that an infant with the
acute form of spinal muscular atrophy will more often than not lack or have an
abnormally small thymus gland- an organ which is involved in immune respons
es in early life. Having an inefficient thymus gland or none at all could impair
immunity and further compromise an infant's weakened condition." (13)
Heredity
When genes are defective, they are unable to properly produce proteins
that are necessary for a cell to be healthy. A destructive chain of events is
triggered when a protein is absent, when there is too little of it, too much, or
if it doesn't work properly for any reason. In the case of SMA, protein abnor
malities prevent the normal functioning of motor neurons, leading to their
deterioration and muscle degeneration.
The infantile and juvenile forms of the disease are usually inherited in
an autosomal recessive pattern- both parents "carry" the defective gene
(without having symptoms), each child has one chance in four of being affected.
Offspring who are unaffected have a two in three chance of being carriers of
the defective gene. (This is demonstrated by computer animation as shown in
the printed example of the final screen of Genetics labled Figure 3B.)
There is currently no method to detect unaffected carriers. SMA some
times appears within a family having no previous history of the disease. Such
"sporadic"
cases may result from a new gene mutation- that is, a disease-
causing gene defect may develop spontaneously in the genetic material. In
other cases, the defective gene can be passed down for generations without
ever being
"expressed,"
so it appears as if the disease never occurred within a
family before.
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SMA is the most common cause of death in infancy, affecting about one in
6,000 babies born worldwide. (14) It is estimated that the number of silent
SMA carriers of the disease gene ranges from one in 40, to one in 80, and if
two carrier parents bestow the gene on their offspring, the babe will be born
with the wasting disease. (15)
The adult forms may be inherited in several patterns- autosomal reces
sive, autosomal dominant, and X-linked. In cases of autosomal dominant inheri
tance, one affected parent can transmit the defective gene to the children, and
each child has one chance in two of inheriting the disease. In X-linked inheri
tance, there is one chance in two that an unaffected mother will pass on the
defective gene to her children, but only boys will develop the symptoms; girls
who inherit the defective gene will be unaffected carriers.
Genetic Testing for SMA
Scientist have discussed the status of genetic testing for SMA and
agreed that, while testing could begin now, it will be more reliable when the
precise nature of the genetic defect has been determined. At this time, scien
tists can identify certain genetic patterns that are associated with the dis
ease in a particular family if affected and unaffected members of a family are
available to donate blood samples for testing. However, routine genetic tests
for SMA awaits the isolation of the precise genetic defect.
Epidemiology
Studies determine that the spinal muscular atrophies are not found in
geographic clusters, since they occur with about the same frequency through
out the world. A 1978 study conducted in England indicated that birthplace,
social class, birth order, and parental age have no apparent influence on the
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occurrence of the infantile form.
Although the spinal muscular atrophies affect both males and females,
the majority of sporadic cases in infancy are males. Other research has shown
that more boys than girls develop the juvenile form and that boys appear to be
more severely affected.
Investigators in Poland have found that the number of cases of the juve
nile form occurring in girls drops significantly after age eight, with virtually
no new cases after age 13. Boys, however, continue to be at risk for develop
ing juvenile spinal muscular atrophy throughout adolescence. Some have spec
ulated that hormonal changes may effectively
"protect"
girls from the disease
after a certain age.
Research Approaches
The axon of a motor neuron (Figure 6) can extend as long as a meter or
more from the cell body to a muscle fiber. A fundamental question facing neu
rologists concerned with what causes motor neurons to deteriorate is, how do
motor neurons manage to survive in healthy individuals? Just how nutrients,
enzymes, and other proteins processed within the cell body are transported
through the long axon to the periphery of the neuron has been a subject of
intensive research.
The Muscular Dystrophy Association supports the world's largest com
prehensive spinal muscular atrophy program, funding promising scientific
investigations into these diseases in an effort to find effective treatments
and cures. The Association makes every effort to support new experimental
treatments whenever there is a reasonable scientific bases for doing so. Under
the auspices of MDA's Medical Advisory Committee and its Task Force on
Therapeutics, Association- funded scientists intensively search for potential
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therapies that might slow, stop or reverse the progress of the disease. (16)
MDA- backed researchers at Columbia University of Colorado Health
Science Center, the University of Pennsylvania, and other institutions are
studying basic mechanisms involved in axonal transport and axonal regenera
tion. Certain unknown factors determine whether an injured neuron survives
and regenerates its axon or dies. Investigators at Israel's Weizmann Institute
of Science are examining the biochemical events that occur when the axon of a
neuron is injured. Their work may open the door to the development of drugs
capable of improving survival and regeneration of neurons damaged by disease.
Trophic Factors
Another area investigators are looking into is trophic factors, which are
substances (ie: chemicals or hormones) that influence muscle development as
well as nerve growth, maintenance, and regeneration. Until recently, little
was known about these factors, but they have been assumed to be crucial to
nerve and muscle survival. Researchers are probing to see if abnormally low
or otherwise impaired trophic factors vital to nerve survival results in the
nerve destruction that characterizes the spinal muscular atrophies. In addition,
researchers at the University of Southern California in Los Angeles and the
University of Wisconsin in Madison are evaluating the interactions of TRH (thy
rotropin- releasing hormone) and nerve cells. TRH may act as a trophic factor,
they have found that it can enhance the survival of motor neurons grown in tis
sue culture. Injections of the hormone have been reported to temporarily
improve the muscle strength of some patients with amyotrophic lateral scle
rosis (ALS), a disease that shares many characteristics with spinal muscular
atrophy. These and other investigators are working to determine how TRH
exerts its influence on nerves and muscles.
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Studies are also being conducted to determine why infants with the acute
form of the disease often lack or have an unusually small thymus, a gland that
is necessary in early life for the immune system to develop normally, as pre
viously mentioned in the section, "Tissue Studies". These kinds of abnormali
ties may impair the immune systems of babies with the infantile and interme
diate types of the disease, worsening their already weakened conditions.
At the University of Chicago, MDA grantees are trying to
determine whether the blood serum of patients with spinal muscular atrophies
and other neuromuscular diseases contains antibodies that attack a trophic
factor secreted by muscle. While previous studies have suggested that thirty
percent of ALS patients have such antibodies in their blood, to date there is no
evidence to suggest that such antibodies are the cause of either ALS or Spinal
Muscular Atrophy.
Why are Motor Neurons Attacked?
Exploring what makes the motor neurons selective targets for destruc
tion in SMA is the purpose of research being conducted under separate MDA
grants to researchers at the University of Southern California and the
University of Chicago. These investigators are using radioactively labeled
antibodies that can
"recognize"
and attack unique structural components of
motor neurons. The radioactive label allows researchers to compare the motor
neurons to other nerve cell types and hopefully determine what makes them
selectively vulnerable in spinal muscular atrophy.
Another approach was introduced when a clinical investigator discovered
that a small percentage of patients with juvenile spinal muscular atrophy have
reduced levels of hexosaminidase, an enzyme that seems to be crucial to nerve
cells of different types. Researchers at the H. Houston Merrit Clinical
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Research Center for Muscular Dystrophy and Related Diseases at Columbia
University have been studying how deficiencies of this enzyme affect different
nerve types causing a variety of disorders, including juvenile SMA and Tay-
Sachs disease, a deadly mental and motor disorder of infancy and early child
hood.
The Columbia team has targeted the genes responsible for producing nor
mal hexosaminidase and mapped out their molecular structures. They are now
seeking possible gene mutations that may account for the different types of
diseases that hexosaminidase deficiency can cause.
Seeking the Gene(s) Responsible
Controversy exists as to whether the many variants of spinal muscular
atrophy are caused by different defective genes. Many have suggested that
separate genes are responsible, if not for all of the variants, at least for the
infantile and juvenile forms. Others are of the opinion that all of the forms
are caused by one basic defect which displays varying degrees of severity and
progression among individuals.
In an effort to shed light on this issue, MDA is funding a study involving
about one hundred families, each of which has one or more members with SMA.
Researchers at the Jerry Lewis Neuromuscular Research Center at the Royal
Postgraduate Medical School in London are collecting blood samples from
patients and as many of their family members as possible. This is the first
step toward screening their chromosomes for clues to the location of gene
defect(s) using advanced techniques of molecular genetics.
Recent Research
Fortunately, rapid advances in gene mapping (a worldwide ongoing pro-
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ject) has provided researchers with breakthrough discoveries regarding SMA.
In 1990, "researchers headed by investigator T. Conrad Gilliam, assistant pro
fessor of neurogenetics at Columbia University in New York, determined that
the chronic childhood forms of SMA are due to a defective gene on chromosome
5." (17) The researchers were also able to deduce that the acute form of
childhood SMA probably results from a defect on the same chromosome perhaps
even within the same gene.
Once the gene (or genes) involved in SMA and the protein the gene makes
have been identified, treatments may be developed that are based on an under
standing of the protein's effects in the body. Even before such treatments
become available, positive genetic identifications will make diagnosis easier
and more accurate.
Until the identification of the genetic defect causing SMA is discovered,
a test is available for some people with a family history of the disorder. A
number of genetic segments that are often inherited along with the defective
gene responsible for SMA have been found by researchers. This information can
be used to make presymptomatic and prenatal diagnosis in some cases. The
genetic test for diagnosis requires blood samples from family members who
have and do not have SMA. Researcher T. Conrad Gilliam of Columbia University
and Integrated Genetics of Framingham, Massachusetts, are both able to test
for the major forms of SMA, while testing for only SMA type I is available in
Boston at the Children's Hospital and at Boston University.
Although the gene was discovered on the proximal arm of chromosome 5,
on the q 13 region, the most probable section for the mutation is between loci
D5S6 and D5S39, and presently there is no proof for genetic heterogeneity in
the disorder. The SMA mutations on chromosome 5 shows consecutive clinical
abnormalities. This strongly suggests that the mutations causing the differing
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severities (or types) of the disease may be different mutations at the same
location similar to the situation observed for Duchenne and Becker Muscular
Dystrophy. .
The possibilities for the future of SMA research look very promising.
Studies have the mutation causing the disease narrowed down to 20-30 million
base pairs of DNA. (18) At this stage, progress will then depend on how quick
ly the gene can be recognized. If the mutation is discovered to be a deletion on
chromosome 5, the gene will be relatively easy to find.
Researchers knew the gene lay somewhere on the lower part of chromo
some No. 5, in a neighborhood called q 13. "The q 13 area is a jumble of redun
dant bases, rat-a-tat-tats of meaningless genetic sequences that make that
part of the chromosome extremely unstable and likely to break apart and lose
pieces of itself. This chromosomal instability probably explains who so many
people carry mutant versions of the SMA gene; (from one in sixty to one in
eighty people are silent carriers of the disease gene); it sits within a part that
gets easily mucked
up."
(19)
Recently, in January 1995, two independent groups of biologists have
reported discovering the cause of SMA. They introduce their findings as
exhibits A and B, two entirely different genes. Both genes sit next to each
other in the same location of chromosome 5, and each team presents substan
tial evidence for why its gene is the correct one. However the nature of SMA
and its inheritance patterns suggest that only one of the two genes is likely to
be the basic cause of the disorder.
In the first case, the gene discovered or the "survival motor neuron
gene"
as it is presently called, is unlike any other gene scientists have discovered.
Judith Melki of the Necker Institute at the Hospital for Sick Children in Paris
and 15 co-workers isolated this discovery.
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Their gene discovered is small and is not associated with any other gene
that scientists have identified to date. This means that researchers do not
know the gene's functions the body or how in its mutant form it may cause
spinal muscular atrophy. Although in support of their case that the gene is the
correct one, the French researchers offer very impressive data.
In their study, the DNA of 229 patients with the disorder was screened.
Scientists have found that the newly identified gene was either partly or
wholly deleted in 226 of them, suggesting that the absence of the gene leads
to the death of the spinal neurons. In the three other patients, researchers
detected confirmation of a specific mutation within the S.M.N, gene. In their
findings, 100 percent of patients with spinal muscular atrophy had distur
bances in the gene, while in patients without the disorder the gene seems nor
mal.
On the other hand, Dr. Alex MacKenzie of the University of Ottawa in
Ontario, and 20 colleagues have discovered a gene that is more medically sen
sible as a potential cause of spinal muscular atrophy. Their gene is similar to
another identified gene that prevents cells from destroying themselves, a nor
mal cellular process called apoptosis. Many nerve cells undergo this explosive
type of cell death during normal development of the brain and spinal cord. Much
evidence indicates that spinal muscular atrophy occurs when the nerve cells
continue apoptosis long after the process is supposed to have terminated.
If the gene the MacKenzie team has identified ordinarily serves to inhibit
neuronal death, then the loss of the gene through mutation could set the stage
for nerve degeneration. With that function in mind, the newly discovered gene
is called "neuronal apoptosis inhibitory
protein."
(20)
Many scientists propose that the loss of the S.M.N, gene is essential for
the onset of spinal muscular atrophy, but that if the neighboring anti-cell sui-
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cide gene is lost as well, the disease will be far worse, possibly as bad as the
lethal type one.
Given both cases, Dr. Gilliam and others familiar with them feel that the
gene discovered by the French team is probably the one responsible for the dis
ease, while the other gene described by the Ottawa group could be a secondary
factor that if mutated, makes the disorder much worse. A simple blood test
for diagnosing SMA either prenatally or in early infancy could soon be devel
oped through new research. Present diagnostic procedures are difficult and
expensive and many require confirmation through a painful muscle biopsy.
Treatments
Today, some 20,000 Americans are affected by SMA. There is no treat
ment beyond physical therapy, to help prolong walking ability and stamina.
Therapy generally consists of treating symptoms related to physical therapy,
exercises to build unaffected muscles, orthopedic aids, and preventing or cor
recting curvature of the spine (scoliosis) through bracing or surgery.
Although exercise is an essential treatment for physical therapy, several
questions about the history of the disease remains: 1. What is the effect of
disease duration on strength on a child with SMA; 2. What is the effect of
exercise or overuse on muscles; 3. Is lost range of motion (ROM) or the devel
opment of contractures, (a shortening which occurs in the muscle in the
absence of any voluntary activity or any electrical signs of muscle activity), a
problem in children with SMA; and 4. How does hand strength relate to func
tion?
The potential benefit of any exercise program for children with muscle
disease has been questioned. In addition, there is continuing controversy over
the use and type of strengthening techniques in children with muscle disease.
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There has been only one published report on the effect of exercise in SMA.
However, in that study group of five children with muscle disease, there were
only three with a diagnosis of SMA II. Dynamic weight training did improve
strength and endurance capabilities of individuals with slowly progressive
muscle disorders without evidence of muscle fiber damage.
Although there is currently no cure for any form of SMA, many drugs have
been tested for their ability to combat these diseases but, thus far, none has
proved capable of halting or reversing motor neuron destruction.
The muscular Dystrophy Association supports the world's largest com
prehensive SMA program funding promising scientific investigations into MDA
diseases in an effort to find effective treatments and cures. Pinpointing the
gene and genetic defect responsible for the illness, makes more accurate diag
nosis possible and provides a crucial step toward developing a treatment.
Conclusion
Spinal Muscular Atrophy (SMA) is an inherited neuromuscular disease that
causes a deterioration of the motor neurons (specifically the Anterior Horn
cells of the spinal cord). These motor neurons that control muscles are selec
tively destroyed resulting in varying degrees of atrophy, weakness, and paraly
sis of the trunk and limb muscles.
There are four basic types of SMA, which are classified according to the
severity of weakness, age at onset of symptoms, and distribution of muscles
affected. Spinal Muscular atrophy is the most common cause of death in infan
cy, afflicting about one in 6,000 babies born worldwide. The disorder ranges
from the very severe, rapidly progressive form, present in infancy, to the rela
tively mild adult form having little or no impact on life expectancy.
It is estimated that the number of silent SMA carriers of the disease
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gene ranges from one in forty, to one in eighty, and if two carrier parents both
bestow the gene on their offspring, the baby will be born with the wasting dis
ease. Today, some 20,000 Americans are affected by SMA and there is no
treatment beyond physical therapy, to help prolong walking ability.
Fortunately, recent discoveries in a worldwide research program, sponsored by
the muscular Dystrophy Association, has found the genetic defect to be on the
q13 region on chromosome 5. Pinpointing the gene and genetic defect respon
sible for the illness, makes more accurate diagnosis possible and provides a
crucial step toward developing a treatment.
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Artwork Report
Computer technology has given the Medical Illustrator another useful tool
to educate various audiences. This body of work is a visual introduction to,
and explanation of Spinal Muscular Atrophy through the aid of interactive
media and animation for the general audience, patients, and their families.
Information in this program was designed to match the background of the
lay public. This also included illustrations which had to explain the disorder
to those who only have a basic understanding of anatomy.
The interactive collection of work is a series of screens that explain
various aspects of SMA and use animation to demonstrate nerve impulses and
heredity. These screens are entitled: Anatomy, Genetics, Muscle, Histology,
The Motorneuron, Affected Muscles, Classification, and Research.
Artwork was either scanned in or created in Adobe Photoshop 2.5 or
Adobe Illustrator 5.5 and imported into Macromind Director 4.0 as pict files.
An interactive program like Director allowed the user to control which screen
to view by activating the mouse button. Such controls as a reverse, menu, and
forward buttons were created to maneuver from screen to screen.
In the development process, the first step was to select the important
issues involving SMA, and to then sketch out each screen to best illustrate
that issue. For the Title, Menu, and Acknowledgments screens, a marbled paper
was chosen. This was also used for the surface color of the buttons. For the
other screens to look uniform, a brown background was also selected. These
were scanned in Photoshop in 72 dpi, or dots per inch, (for screen viewing and
to save memory). (The brown background was also scanned in at 150 dpi to be
used in separate files for printing purposes.)
The first screen, or Figure 2, focuses upon the anatomy of the Central
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Nervous System (CNS) and the Anterior Horn cells that are affected. For this
screen, pen and ink drawings of the CNS and a transverse section of the spinal
cord were scanned in at 72 dpi and colorized in Photoshop.
Using animation, this second screen, or Figures 3A and 3B, explains the
autosomal recessive pattern in which an SMA gene is passed to a child by car
rier parents. To design this screen, two human figures, and the chromosome
was created in Adobe Illustrator 5.5 and brought into Photoshop to be col
orized.
Figure 4 illustrates the anatomy of a healthy muscle, its fascicles, and
myofibrils and was developed in the same manner as Figure 2.
The fourth screen, or Figure 5, shows two examples of histology sections
of healthy muscle and muscle affected by SMA. The SMA affected muscle par
ticularly shows the difference between atrophied, hypertrophied, and normal
muscle fibers. This involved scanning two black and white photographic exam
ples of muscle tissue and colorizing them. Alterations had to be made to clar
ify the fibers and connective tissue to bring out the texture.
Figure 6 is a dynamic view of the motorneuron and muscle with animated
theories of normal, partial, and failed nerve impulses and muscle spasm.
With superimposed muscles over a human body, this sixth screen, or
Figure 7, presents the specific muscle groups that SMA weakens. For experi
mental purposes in this screen, muscles were drawn in colored pencil on vel
lum over a black and white photograph of a model. The photograph was then
scanned into Photoshop and the opacity reduced for a
"ghosting"
effect. The
vellum drawing was also scanned and adjusted in Photoshop and then superim
posed on the nude image.
Figure 8 describes the four types of SMA by using a simple horizontal bar
chart. By depressing the mouse on each bar, a separate window pops up
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explaining the characteristics of that type.
In this last screen, or Figure 9, a large chromosome 5 illustrates the
region in which the SMA gene is believed to be. This screen describes the lat
est research including the discovery of two suspected genes that cause SMA.
In creating this screen, the chromosome was drawn in Illustrator and imported
and colorized in Photoshop. In the background, a pattern of chromosomes was
made by using the "skew" effect, reducing the opacity (so as not to conflict
with the large chromosome in the foreground and type), and then dragging
copies of it using the
"option" key.
All images and backgrounds were saved as pict files and imported into
Macromind Director as cast members. Assembling each screen was then done
by dragging each cast member onto the stage. All of the shadowed text was
used in Director for simplicity and used as cast members. (This enabled me to
move and change text if I needed to, unlike a set image imported from Adobe
Photoshop 2.5.) A title, menu, and acknowledgment page was created. In the
menu screen, labeled Figure 1, the user can access any of the eight screens by
clicking on their prospective buttons. Once on a titled screen, the viewer can
move forward, backward, or to the menu by using the Lingo-programmed but
tons; at the
"Acknowledgment"
screen, the user has the option of moving back
ward, or exiting.
Once all the screens were completed, a projector file was made so the
viewer could open and close it. This was necessary because the computer
would have to be on during Bevier Gallery hours and the viewer would need to
access the program at any time.
In order for the animations to run quickly and smoothly, the computer had
to be comparable to a Quadra or Power Mac. This is because the computer's
speed had to run fast enough (60 megahertz or more) to load each frame for
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15-25 frames per second. Unfortunately, there is a shortage of fast computers
to borrow from the computer labs for the full duration of the thesis show.
However, due to the color quality that I strived for, I felt this dilemma
may have been eased if a 256 color palate was used instead of thousands. The
second step to solve this problem was to create a duplicate file with a sepa
rate color palate of 256 colors, and adjust all the cast members to the new
palate; but this didn't help an older, slower computer from loading and running
the animations any faster. In any case, this was a valuable learning experi
ence.
To my knowledge, in Macromind Director, there is no way of exporting one
frame for printing, and since it would be in 72 dpi, quality would be poor. To
save as pieces for my portfolio, certain images were not only saved in 72 dpi
for the screen, but in 150-200 dpi for printing. These four pieces were recre
ated (as close as possible) to the way the original screens looked.
(Unfortunately, the background and muscle colors were not Pantone colors, and
thus printed very dark and muted.) Type was also done in Photoshop (with
anti-aliased on) because of better color choices. (Quark Express 3.3 choices
for color type were limited). Eventually the whole projector file could be
saved onto a compact disk to educate the lay public, patients, and their fami
lies about Spinal Muscular Atrophy.
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Screen Artwork
The opposite pages are color copies of the printed versions of screens shown
in Macromind Director 4.0:
1. Figure 1
Menu
Abobe Photoshop 2.5,
Macromind Director 4.0
2. Figure 2
Anatomy
Pen and ink, Abobe Photoshop 2.5
3. Figure 3A
Genetics-
screen before animation
Abobe Illustrator 5.5,
Abobe Photoshop 2.5
4. Figure 3B
Genetics-
screen after animation is completed
Abobe Illustrator 5.5,
Abobe Photoshop 2.5
5. Figure 4
Muscle
Pen and ink, Abobe Photoshop 2.5
6. Figure 5
Histology
Black and white histology
photographs, Abobe Photoshop 2.5
7. Figures 6, 6A-6D
Motorneuron
Abobe Illustrator 5.5,
Abobe Photoshop 2.5
8. Figure 7
Affected Muscles
Black and white photograph,
colored pencil, Abobe Photoshop 2.5
9. Figure 8
Classification
Abobe Photoshop 2.5,
Macromind Director 4.0
10. Figure 9
Research
Abobe Illustrator 5.5,
Abobe Photoshop 2.5,
Macromind Director 4.0
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